December 21, 2009
Spiriva HandiHaler approved for the reduction of COPD exacerbations
The Spiriva HandiHaler prescribing information now also includes data from the UPLIFT study which demonstrated that Spiriva HandiHaler sustained improved lung function over four years when compared with placebo and reduced COPD exacerbations, even with the use of respiratory medications with the exception of inhaled anticholinergics.
Spiriva HandiHaler is already indicated for the long-term maintenance treatment of bronchospasm due to chronic bronchitis and emphysema.
For more information call (800) 542-6257 or visit www.spiriva.com.